Cargando…

Impact of the revised WHO classification of diffuse low-grade glioma on clinical decision making: A case report

BACKGROUND: In the 2016 update of the World Health Organization Classification of Tumors of the central nervous system, phenotypic and genotypic parameters are integrated in diffuse low-grade glioma (LGG) tumor classification. Implementation of this combined phenotypic–genotypic characterization ide...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Vlis, Tim A. M. Bouwens, Hoeben, Ann, Beckervordersandforth, Jan C., Ackermans, Linda, Eekers, Daniëlle B. P., Wennekes, Rianne M. J., Schijns, Olaf E. M. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609445/
https://www.ncbi.nlm.nih.gov/pubmed/28966829
http://dx.doi.org/10.4103/sni.sni_166_17
Descripción
Sumario:BACKGROUND: In the 2016 update of the World Health Organization Classification of Tumors of the central nervous system, phenotypic and genotypic parameters are integrated in diffuse low-grade glioma (LGG) tumor classification. Implementation of this combined phenotypic–genotypic characterization identifies prognostic relevant subgroups. CASE DESCRIPTION: We report a case of a 67-year-old patient with an LGG that showed molecular characteristics similar to glioblastoma multiforme (GBM). After gross total tumor resection, the patient received combination therapy (radiotherapy and chemotherapy) according to high-grade glioma treatment protocol. CONCLUSION: The introduction of molecular parameters to the classification of LGG will add a level of objectivity, which will yield biological homogeneous subclasses. Consequently, this will influence patient counseling and clinical decision making regarding treatment protocols.